Aurinia Pharmaceuticals Inc (AUPH)

Etorro trading 970x250

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada. Address: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8

Aurinia Pharmaceuticals Inc News and around…

Latest news about Aurinia Pharmaceuticals Inc (AUPH) common stock and company :

2 Biotech Stocks That Could Go Parabolic This Week
24 Oct, 2021 FinancialContent

These stocks could soon take flight.

Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today
23 Oct, 2021 FinancialContent

The biotech is reportedly in buyout talks with Bristol Myers Squibb.

Bristol Myers interested in buying Aurinia Pharma - Bloomberg News
22 Oct, 2021 Yahoo! Finance

Aurinia's shares closed up nearly 27% on the news, giving it a market capitalization of $3.59 billion, according to Refinitiv data. The report said no final decision has been made and that Bristol Myers could opt out of a potential deal. Both Bristol Myers and Aurinia declined to comment on the matter.

Rumored Bristol Myers Takeover Sends Aurinia Pharma Stock To A Record High
22 Oct, 2021 FinancialContent

Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying to a record high on Friday.

Aurinia Pharma Stock Pops On Reports Of Looming Bristol Myers Takeover
22 Oct, 2021 FinancialContent

Bristol Myers is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying before it was halted.

Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals
22 Oct, 2021 Yahoo! Finance

(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter. Most Read from BloombergWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeCities' Answer to Sprawl? Go Wild.One of California’s Wealthiest Counties Could Run Out of Water Next SummerHamburg Is at the Heart of Germany’s Growing D

More Chinese Trouble
14 Oct, 2021 FinancialContent

A day after the consumer price rise there was another price rise for producer markets.

A Bit Of A Recovery
29 Sep, 2021 FinancialContent

While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week.

2 Best Biotech Stocks to Buy Right Now
25 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Pharma, Tech and Finance
20 Sep, 2021 FinancialContent

Good news on some drugs was not enough to boost stock markets.

Implied Volatility Surging for Aurinia (AUPH) Stock Options
20 Sep, 2021 Yahoo! Finance

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
15 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
15 Sep, 2021 Yahoo! Finance

VICTORIA, British Columbia, September 15, 2021--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that members of the senior management team will present at the following upcoming virtual investor conferences:

First Week of AUPH January 2024 Options Trading
15 Sep, 2021 FinancialContent

Investors in Aurinia Pharmaceuticals Inc (AUPH) saw new options begin trading this week, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Notable Aurinia Pharmaceuticals Insider Trades $2.92 Million In Company Stock
15 Sep, 2021 Yahoo! Finance

Michael Robert Martin, Chief Business Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), made a large buy and sell of company shares on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Michael Robert Martin purchased 115,000 Aurinia Pharmaceuticals shares at prices ranging from $3.20 to $5.30 per share for a total of $515,000 on September 14. They then sold their shares on multiple transactions in the open mar

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Sunday Special
12 Sep, 2021 FinancialContent

I have a taste for nuclear electricity which France pioneered decades ago, building power stations along the Loire Valley and in other regions. So I took my taste for uranium into my US holdings.

Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
10 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be available on-demand beginning September 13, 2021 at 3 pm ET.

Best Stocks To Invest In Right Now? 4 Health Care Stocks To Know
10 Sep, 2021 FinancialContent
Stocks To Watch: Aurinia Pharmaceuticals Sees Relative Strength Rating Jump To 92
09 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Post-Rosh Hashanah, Sell?
09 Sep, 2021 FinancialContent

As the saying goes, sell Rosh Hashanah and buy Yom Kippur. Does it apply this year?

Aurinia Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark
03 Sep, 2021 FinancialContent

Aurinia Pharmaceuticals sees its Relative Strength Rating hit the 80-plus level.

Stocks Generating Improved Relative Strength: Aurinia Pharmaceuticals
02 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Aurinia Pharmaceuticals shows improving technical performance. Will it continue?

Aurinia Pharmaceuticals Shows Rising Relative Strength
27 Aug, 2021 Yahoo! Finance

Aurinia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 84.

Stock Upgrades: Aurinia Pharmaceuticals Shows Rising Relative Strength
27 Aug, 2021 FinancialContent

Aurinia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 84.

The five-year returns have been massive for Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders despite underlying losses increasing
26 Aug, 2021 Yahoo! Finance

Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...

Aurinia Pharmaceuticals Sees Relative Strength Rating Improve To 73
26 Aug, 2021 FinancialContent

Aurinia Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline
18 Aug, 2021 Yahoo! Finance

Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.

Aurinia Pharmaceuticals Inc (AUPH) is a NASDAQ Common Stock listed in , ,

970x250